BriaCell Therapeutics is moving forward with off-the-shelf whole cell immunotherapies for late-stage cancers, with pivotal trials underway and new FDA clearance for prostate cancer.
Cardinal Health is aiming for 13 to 15 percent adjusted EPS growth in fiscal 2027, driven by momentum in its specialty segment and investments in oncology, urology, and autoimmune care.
AbbVie is betting on a multimodal approach in lung cancer by combining bispecific antibodies with antibody-drug conjugates, aiming to overcome resistance and improve patient outcomes as new clinical data emerges.
Gujarat Themis Biosyn Limited has closed its Rs 1,200 crore deal to acquire MicroBiopharm Japan, gaining new biologics capabilities and a direct presence in regulated global markets.
Latus Bio has named Donald Hayden as chairman and Michael MacLean as independent director, strengthening its board as the company prepares to start clinical trials for gene therapies targeting CLN2 disease and Huntington’s disease.
Lōkahi Therapeutics is strengthening its collaboration with The University of Alabama’s Culverhouse College of Business, giving students direct experience in evaluating real biopharma assets through the ai² Pipeline division.
Bristol Myers Squibb has stopped work on ORM-6151, a degrader-antibody conjugate from Orum Therapeutics, after reviewing Phase I trial data.
Holtec Nuclear abruptly postponed its $825 million IPO while Nscale filed for a potential $2 billion offering and Electra Therapeutics suffered a rare biotech IPO drop.
A surge of more than 180 companies is driving over 200 CAR-T therapies through the clinical pipeline, with new strategies aiming to overcome resistance and expand beyond cancer.
North Carolina’s life sciences sector is taking a measured approach to growth, favoring smaller, risk-managed deals and targeted expansions, while a few major players make billion-dollar commitments.
Bristol Myers Squibb has stopped development of Orum Therapeutics' CD33-targeted AML drug, erasing USD 80 million in milestone payments and leaving only one approved agent in the clinical-stage DAC field.
Dualitas Therapeutics has signed a $36.5 million upfront agreement with Roche for access to its DualScreen Bispecific Discovery Engine, with total payments that could reach $1 billion.
Arovella Therapeutics has received FDA clearance to begin Phase 1 clinical testing of its allogeneic cell therapy ALA-101 targeting CD19-positive blood cancers.
SK Biopharmaceuticals has signed a licensing and equity agreement with 1ST Biotherapeutics, gaining exclusive global rights to a preclinical Parkinson's disease candidate with a dual-inhibition mechanism.
